ATTO
Attovia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.55
+5.58%Latest reported
- Last report date
- Sep 2, 2026
- EPS actual
- -$4.88
- EPS estimate
- -$0.65
- Revenue actual
- $450.0K
- Revenue estimate
- $316.7K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 0
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -655.5%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $42
- PT range
- $30 – $52
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Sep 2, 2026